- Home
- CSCI vs PHGE Comparison
CSCI vs PHGE Comparison
Compare CSCI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- PHGE
- Stock Information
- Founded
- CSCI 1990
- PHGE 2015
- Country
- CSCI Canada
- PHGE Israel
- Employees
- CSCI N/A
- PHGE N/A
- Industry
- CSCI
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- CSCI
- PHGE Health Care
- Exchange
- CSCI NYSE
- PHGE Nasdaq
- Market Cap
- CSCI 11.1M
- PHGE 11.1M
- IPO Year
- CSCI 1996
- PHGE N/A
- Fundamental
- Price
- CSCI $2.66
- PHGE $0.61
- Analyst Decision
- CSCI
- PHGE Strong Buy
- Analyst Count
- CSCI 0
- PHGE 2
- Target Price
- CSCI N/A
- PHGE $22.50
- AVG Volume (30 Days)
- CSCI 4.7K
- PHGE 73.2K
- Earning Date
- CSCI 11-12-2024
- PHGE 11-14-2024
- Dividend Yield
- CSCI N/A
- PHGE N/A
- EPS Growth
- CSCI N/A
- PHGE N/A
- EPS
- CSCI N/A
- PHGE N/A
- Revenue
- CSCI $4,834,000.00
- PHGE N/A
- Revenue This Year
- CSCI N/A
- PHGE N/A
- Revenue Next Year
- CSCI N/A
- PHGE N/A
- P/E Ratio
- CSCI N/A
- PHGE N/A
- Revenue Growth
- CSCI N/A
- PHGE N/A
- 52 Week Low
- CSCI $2.62
- PHGE $0.48
- 52 Week High
- CSCI $11.10
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- PHGE 42.68
- Support Level
- CSCI N/A
- PHGE $0.61
- Resistance Level
- CSCI N/A
- PHGE $0.69
- Average True Range (ATR)
- CSCI 0.00
- PHGE 0.08
- MACD
- CSCI 0.00
- PHGE 0.01
- Stochastic Oscillator
- CSCI 0.00
- PHGE 10.05
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.